Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML)
that is used for prognostic, predictive, monitoring, and efficacy-response assessments. …

Genetic heterogeneity contributes to clinical outcome and progression of most tumors, but
little is known about allelic diversity for epigenetic compartments, and almost no data exist for …

Purpose We investigated the effect on outcome of measurable or minimal residual disease (MRD)
status after each induction course to evaluate the extent of its predictive value for …

PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative
potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid …

Relapse remains the most common cause of treatment failure for patients with acute myeloid
leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a …

… Richard Dillon, Richard Dillon … Sun Loo, Richard Dillon, Adam Ivey, Natasha S. Anstee,
Jad Othman, Ing Soo Tiong, Nicola Potter, Jelena Jovanovic, Manohursingh Runglall, Chyn …

The neurological status of 9− and 30-day-old infants, as assessed by the Prechtl neurological
examination, was significantly and differentially related to prenatal exposure of cigarettes, …

Background: There is insufficient evidence to support clinical decision-making for cancer
patients diagnosed with COVID-19 due to the lack of large studies. Methods: We used data …

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated
patients with NPM1 mut measurable residual disease (MRD) using off‐label venetoclax in …

Several comprehensive User Centred Design methodologies have been published in the
last decade, but while they all focus on users, they disagree on exactly what activities should …